Formed in 1983, CEL-SCI Corporation is a biotechnology company conducting drug discovery, research, development, and manufacturing of complex biological substances. Its pipeline centers on investigational immune-based therapies, including Multikine, developed for potential use in cancer, and LEAPS candidates for autoimmune and infectious diseases. The company operates a dedicated manufacturing facility for investigational Multikine.
Good Manufacturing Practices (GMP)
Compliance program
Current Good Manufacturing Practice (cGMP)
Compliance program
GMP
Quality certification
Medigen, IncMedigen, Inc. is a biomedical and vaccine company developing vaccines for emerging infectious diseases, chronic diseases including cancer, and other biopharmaceutical applications. Its explicitly described capabilities include vaccine manufacturing, cGMP production of cell and virus banks, virus and protein drug substance production, fill-finish, VLP design and production, molecular biology, electron microscopy, protein expression, and protein purification.FREDERICK, MD
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
Bristol Myers SquibbBristol Myers Squibb is a global biopharmaceutical company that discovers, develops and delivers medicines for serious diseases. Its research and manufacturing network is especially focused on oncology, hematology and cell therapy, including personalized CAR T therapies made at facilities in Washington and New Jersey. The company traces its scientific legacy to the early 1800s and has maintained continuous operations at its New Brunswick site since 1905.NEW YORK, NY
ResilienceNational Resilience, Inc. is a technology-focused biomanufacturing company founded in 2020 to broaden access to complex medicines and strengthen biopharmaceutical supply chains. It operates an end-to-end manufacturing network across North America, supporting development and production of medicines from early phase through commercial manufacturing. Its facilities produce drug substances and drug products, including cell therapies and vaccines.BLUE ASH, OH